These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 19625640)

  • 1. HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection.
    Bonsignori M; Moody MA; Parks RJ; Holl TM; Kelsoe G; Hicks CB; Vandergrift N; Tomaras GD; Haynes BF
    J Immunol; 2009 Aug; 183(4):2708-17. PubMed ID: 19625640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
    Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X
    J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate.
    Forthal DN; Gilbert PB; Landucci G; Phan T
    J Immunol; 2007 May; 178(10):6596-603. PubMed ID: 17475891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An HIV-1 envelope immunogen with W427S mutation in CD4 binding site induced more T follicular helper memory cells and reduced non-specific antibody responses.
    Yu HT; Tian D; Wang JY; Guo CX; Li Y; Wang X; Li D; Zhang FM; Zhuang M; Ling H
    PLoS One; 2014; 9(12):e115047. PubMed ID: 25546013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits.
    Jiang X; Totrov M; Li W; Sampson JM; Williams C; Lu H; Wu X; Lu S; Wang S; Zolla-Pazner S; Kong XP
    J Virol; 2016 Dec; 90(24):11007-11019. PubMed ID: 27707920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
    Bower JF; Green TD; Ross TM
    Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection.
    Guan Y; Sajadi MM; Kamin-Lewis R; Fouts TR; Dimitrov A; Zhang Z; Redfield RR; DeVico AL; Gallo RC; Lewis GK
    Proc Natl Acad Sci U S A; 2009 Mar; 106(10):3952-7. PubMed ID: 19225108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine.
    McGuire EP; Fong Y; Toote C; Cunningham CK; McFarland EJ; Borkowsky W; Barnett S; Itell HL; Kumar A; Gray G; McElrath MJ; Tomaras GD; Permar SR; Fouda GG
    J Virol; 2018 Jan; 92(1):. PubMed ID: 29021402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV Env-Specific IgG Antibodies Induced by Vaccination of Neonatal Rhesus Macaques Persist and Can Be Augmented by a Late Booster Immunization in Infancy.
    Curtis AD; Dennis M; Eudailey J; Walter KL; Cronin K; Alam SM; Choudhary N; Tuck RH; Hudgens M; Kozlowski PA; Pollara J; Ferrari G; Van Rompay KKA; Permar S; De Paris K
    mSphere; 2020 Mar; 5(2):. PubMed ID: 32213623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans.
    Pissani F; Schulte B; Eller MA; Schultz BT; Ratto-Kim S; Marovich M; Thongcharoen P; Sriplienchan S; Rerks-Ngarm S; Pitisuttithum P; Esser S; Alter G; Robb ML; Kim JH; Michael NL; Streeck H
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30209165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
    Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
    Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
    Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
    J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abnormal B cell memory subsets dominate HIV-specific responses in infected individuals.
    Kardava L; Moir S; Shah N; Wang W; Wilson R; Buckner CM; Santich BH; Kim LJ; Spurlin EE; Nelson AK; Wheatley AK; Harvey CJ; McDermott AB; Wucherpfennig KW; Chun TW; Tsang JS; Li Y; Fauci AS
    J Clin Invest; 2014 Jul; 124(7):3252-62. PubMed ID: 24892810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A).
    Staats HF; Nichols WG; Palker TJ
    J Immunol; 1996 Jul; 157(1):462-72. PubMed ID: 8683152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant HIV-1 glycoprotein 120 induces distinct types of delayed hypersensitivity in persons with or without pre-existing immunologic memory.
    Hladik F; Bender S; Akridge RE; Hu YX; Galloway C; Francis D; McElrath MJ
    J Immunol; 2001 Mar; 166(5):3580-8. PubMed ID: 11207319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone marrow plasma cells are a primary source of serum HIV-1-specific antibodies in chronically infected individuals.
    Montezuma-Rusca JM; Moir S; Kardava L; Buckner CM; Louie A; Kim LJ; Santich BH; Wang W; Fankuchen OR; Diaz G; Daub JR; Rosenzweig SD; Chun TW; Li Y; Braylan RC; Calvo KR; Fauci AS
    J Immunol; 2015 Mar; 194(6):2561-8. PubMed ID: 25681347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brucella abortus conjugated with a gp120 or V3 loop peptide derived from human immunodeficiency virus (HIV) type 1 induces neutralizing anti-HIV antibodies, and the V3-B. abortus conjugate is effective even after CD4+ T-cell depletion.
    Golding B; Inman J; Highet P; Blackburn R; Manischewitz J; Blyveis N; Angus RD; Golding H
    J Virol; 1995 Jun; 69(6):3299-307. PubMed ID: 7745677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
    Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX
    AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural Comparison of Human Anti-HIV-1 gp120 V3 Monoclonal Antibodies of the Same Gene Usage Induced by Vaccination and Chronic Infection.
    Chan KW; Pan R; Costa M; Gorny MK; Wang S; Lu S; Kong XP
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29997214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.